Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 7.15
SUPN's Cash to Debt is ranked higher than
65% of the 729 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.63 vs. SUPN: 7.15 )
Ranked among companies with meaningful Cash to Debt only.
SUPN' s Cash to Debt Range Over the Past 10 Years
Min: 0.19  Med: 2.75 Max: No Debt
Current: 7.15
Equity to Asset 0.66
SUPN's Equity to Asset is ranked higher than
55% of the 677 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. SUPN: 0.66 )
Ranked among companies with meaningful Equity to Asset only.
SUPN' s Equity to Asset Range Over the Past 10 Years
Min: -2.25  Med: 0.35 Max: 0.68
Current: 0.66
-2.25
0.68
Interest Coverage 7.09
SUPN's Interest Coverage is ranked lower than
80% of the 470 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 123.58 vs. SUPN: 7.09 )
Ranked among companies with meaningful Interest Coverage only.
SUPN' s Interest Coverage Range Over the Past 10 Years
Min: 1  Med: 2.94 Max: 4.88
Current: 7.09
1
4.88
F-Score: 6
Z-Score: 6.04
M-Score: -1.60
WACC vs ROIC
10.79%
38.87%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) 11.73
SUPN's Operating margin (%) is ranked higher than
60% of the 686 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.82 vs. SUPN: 11.73 )
Ranked among companies with meaningful Operating margin (%) only.
SUPN' s Operating margin (%) Range Over the Past 10 Years
Min: -37851.89  Med: -515.18 Max: 27.1
Current: 11.73
-37851.89
27.1
Net-margin (%) 8.67
SUPN's Net-margin (%) is ranked higher than
59% of the 687 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.45 vs. SUPN: 8.67 )
Ranked among companies with meaningful Net-margin (%) only.
SUPN' s Net-margin (%) Range Over the Past 10 Years
Min: -36285.85  Med: -376.67 Max: 6701.74
Current: 8.67
-36285.85
6701.74
ROE (%) 12.95
SUPN's ROE (%) is ranked higher than
68% of the 715 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.30 vs. SUPN: 12.95 )
Ranked among companies with meaningful ROE (%) only.
SUPN' s ROE (%) Range Over the Past 10 Years
Min: -202.72  Med: -141.55 Max: 37.92
Current: 12.95
-202.72
37.92
ROA (%) 7.94
SUPN's ROA (%) is ranked higher than
70% of the 740 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.67 vs. SUPN: 7.94 )
Ranked among companies with meaningful ROA (%) only.
SUPN' s ROA (%) Range Over the Past 10 Years
Min: -90.03  Med: -30.02 Max: 106.84
Current: 7.94
-90.03
106.84
ROC (Joel Greenblatt) (%) 179.03
SUPN's ROC (Joel Greenblatt) (%) is ranked higher than
96% of the 735 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.76 vs. SUPN: 179.03 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
SUPN' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -4247.75  Med: -2739.56 Max: 1356
Current: 179.03
-4247.75
1356
Revenue Growth (3Y)(%) 68.90
SUPN's Revenue Growth (3Y)(%) is ranked higher than
97% of the 585 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. SUPN: 68.90 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
SUPN' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 34.45 Max: 75.7
Current: 68.9
0
75.7
» SUPN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2014

SUPN Guru Trades in Q4 2014

Paul Tudor Jones 13,966 sh (New)
Jim Simons 157,049 sh (+327.93%)
Robert Bruce 694,581 sh (+73.65%)
» More
Q1 2015

SUPN Guru Trades in Q1 2015

George Soros 107,308 sh (New)
Joel Greenblatt 41,686 sh (New)
Paul Tudor Jones 42,987 sh (+207.80%)
Robert Bruce 694,581 sh (unchged)
Jim Simons Sold Out
» More
Q2 2015

SUPN Guru Trades in Q2 2015

Jim Simons 115,000 sh (New)
Joel Greenblatt 88,267 sh (+111.74%)
Robert Bruce 694,581 sh (unchged)
George Soros Sold Out
Paul Tudor Jones 24,900 sh (-42.08%)
» More
Q3 2015

SUPN Guru Trades in Q3 2015

Paul Tudor Jones 33,600 sh (+34.94%)
Jim Simons 125,100 sh (+8.78%)
Robert Bruce 394,581 sh (-43.19%)
Joel Greenblatt 39,142 sh (-55.66%)
» More
» Details

Insider Trades

Latest Guru Trades with SUPN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 58.31
SUPN's P/E(ttm) is ranked lower than
77% of the 499 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 28.00 vs. SUPN: 58.31 )
Ranked among companies with meaningful P/E(ttm) only.
SUPN' s P/E(ttm) Range Over the Past 10 Years
Min: 0.14  Med: 31.90 Max: 97.53
Current: 58.31
0.14
97.53
PE(NRI) 54.48
SUPN's PE(NRI) is ranked lower than
75% of the 496 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 28.20 vs. SUPN: 54.48 )
Ranked among companies with meaningful PE(NRI) only.
SUPN' s PE(NRI) Range Over the Past 10 Years
Min: 13.23  Med: 25.87 Max: 91.17
Current: 54.48
13.23
91.17
P/B 5.56
SUPN's P/B is ranked lower than
78% of the 706 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.79 vs. SUPN: 5.56 )
Ranked among companies with meaningful P/B only.
SUPN' s P/B Range Over the Past 10 Years
Min: 3.23  Med: 6.87 Max: 18.63
Current: 5.56
3.23
18.63
P/S 4.72
SUPN's P/S is ranked lower than
68% of the 675 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.72 vs. SUPN: 4.72 )
Ranked among companies with meaningful P/S only.
SUPN' s P/S Range Over the Past 10 Years
Min: 3.22  Med: 15.63 Max: 157
Current: 4.72
3.22
157
PFCF 36.86
SUPN's PFCF is ranked lower than
51% of the 248 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. SUPN: 36.86 )
Ranked among companies with meaningful PFCF only.
SUPN' s PFCF Range Over the Past 10 Years
Min: 16.41  Med: 37.71 Max: 452
Current: 36.86
16.41
452
POCF 33.87
SUPN's POCF is ranked lower than
54% of the 384 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.79 vs. SUPN: 33.87 )
Ranked among companies with meaningful POCF only.
SUPN' s POCF Range Over the Past 10 Years
Min: 16.07  Med: 34.65 Max: 180.8
Current: 33.87
16.07
180.8
EV-to-EBIT 38.98
SUPN's EV-to-EBIT is ranked lower than
75% of the 515 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 20.63 vs. SUPN: 38.98 )
Ranked among companies with meaningful EV-to-EBIT only.
SUPN' s EV-to-EBIT Range Over the Past 10 Years
Min: -402.1  Med: -2.50 Max: 71.3
Current: 38.98
-402.1
71.3
EV-to-EBITDA 36.75
SUPN's EV-to-EBITDA is ranked lower than
77% of the 540 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.42 vs. SUPN: 36.75 )
Ranked among companies with meaningful EV-to-EBITDA only.
SUPN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -4453.5  Med: -2.50 Max: 67.2
Current: 36.75
-4453.5
67.2
Current Ratio 2.38
SUPN's Current Ratio is ranked higher than
52% of the 713 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.27 vs. SUPN: 2.38 )
Ranked among companies with meaningful Current Ratio only.
SUPN' s Current Ratio Range Over the Past 10 Years
Min: 1.51  Med: 3.26 Max: 7.26
Current: 2.38
1.51
7.26
Quick Ratio 2.04
SUPN's Quick Ratio is ranked higher than
59% of the 713 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.65 vs. SUPN: 2.04 )
Ranked among companies with meaningful Quick Ratio only.
SUPN' s Quick Ratio Range Over the Past 10 Years
Min: 1.51  Med: 3.09 Max: 7.26
Current: 2.04
1.51
7.26
Days Inventory 614.84
SUPN's Days Inventory is ranked lower than
98% of the 643 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 118.46 vs. SUPN: 614.84 )
Ranked among companies with meaningful Days Inventory only.
SUPN' s Days Inventory Range Over the Past 10 Years
Min: 652.7  Med: 1012.71 Max: 1372.72
Current: 614.84
652.7
1372.72
Days Sales Outstanding 64.98
SUPN's Days Sales Outstanding is ranked higher than
58% of the 585 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 75.01 vs. SUPN: 64.98 )
Ranked among companies with meaningful Days Sales Outstanding only.
SUPN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 2.71  Med: 72.56 Max: 16387.12
Current: 64.98
2.71
16387.12
Days Payable 129.76
SUPN's Days Payable is ranked higher than
78% of the 558 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 72.59 vs. SUPN: 129.76 )
Ranked among companies with meaningful Days Payable only.
SUPN' s Days Payable Range Over the Past 10 Years
Min: 118.1  Med: 578.45 Max: 1038.8
Current: 129.76
118.1
1038.8

Valuation & Return

vs
industry
vs
history
Price/Net Cash 1254.00
SUPN's Price/Net Cash is ranked lower than
99% of the 201 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.02 vs. SUPN: 1254.00 )
Ranked among companies with meaningful Price/Net Cash only.
SUPN' s Price/Net Cash Range Over the Past 10 Years
Min: 4.22  Med: 29.97 Max: 1403
Current: 1254
4.22
1403
Price/Net Current Asset Value 13.48
SUPN's Price/Net Current Asset Value is ranked lower than
72% of the 465 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.70 vs. SUPN: 13.48 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
SUPN' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 3.98  Med: 13.68 Max: 42.12
Current: 13.48
3.98
42.12
Price/Tangible Book 6.57
SUPN's Price/Tangible Book is ranked lower than
74% of the 656 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.51 vs. SUPN: 6.57 )
Ranked among companies with meaningful Price/Tangible Book only.
SUPN' s Price/Tangible Book Range Over the Past 10 Years
Min: 3.85  Med: 6.76 Max: 19.29
Current: 6.57
3.85
19.29
Price/Median PS Value 0.30
SUPN's Price/Median PS Value is ranked higher than
95% of the 612 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.18 vs. SUPN: 0.30 )
Ranked among companies with meaningful Price/Median PS Value only.
SUPN' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.21  Med: 1.18 Max: 8.14
Current: 0.3
0.21
8.14
Price/Graham Number 3.99
SUPN's Price/Graham Number is ranked lower than
80% of the 479 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.07 vs. SUPN: 3.99 )
Ranked among companies with meaningful Price/Graham Number only.
SUPN' s Price/Graham Number Range Over the Past 10 Years
Min: 2.11  Med: 2.78 Max: 4.47
Current: 3.99
2.11
4.47
Earnings Yield (Greenblatt) (%) 2.57
SUPN's Earnings Yield (Greenblatt) (%) is ranked lower than
54% of the 723 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. SUPN: 2.57 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
SUPN' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 1.4  Med: 4.70 Max: 10.5
Current: 2.57
1.4
10.5

More Statistics

Revenue(Mil) $133
EPS $ 0.22
Beta1.15
Short Percentage of Float10.60%
52-Week Range $8.32 - 23.30
Shares Outstanding(Mil)48.92

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare: » details
Traded in other countries:S49.Germany,
Supernus Pharmaceuticals Inc was incorporated in Delaware on March 30, 2005. The Company is a specialty pharmaceutical company engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The Company markets two epilepsy products, Oxtellar XR and Trokendi XR, and has other proprietary product candidates in clinical development that address the psychiatry market. The Company is developing multiple product candidates in psychiatry to address the unmet medical needs and market opportunities in impulsive aggression across several areas including attention deficit hyperactivity disorder (ADHD), autism and bipolar disorder, and ADHD. The Company's neurology portfolio consists of Oxtellar XR and Trokendi XR. Oxtellar XR is indicated for adjunctive therapy of partial seizures in adults and in children 6 years to 17 years of age and Trokendi XR is indicated for initial monotherapy in patients 10 years of age and older with partial onset or primary generalized tonic-clonic seizures, and as adjunctive therapy in patients 6 years of age and older with partial onset or primary generalized tonic-clonic seizures or with seizures associated with Lennox-Gastaut syndrome. Its psychiatry product candidates include ADHD, SPN-810 (molindone hydrochloride) and SPN-812 (viloxazine hydrochloride). ADHD is a common CNS disorder characterized by developmentally inappropriate levels of inattention, hyperactivity, and impulsivity; and it develops SPN-810 (molindone hydrochloride) as a treatment for impulsive aggression in patients with ADHD in conjunction with standard ADHD treatment. The Company has a portfolio of drug development technologies consisting of platforms including Microtrol, Solutrol and EnSoTrol. It is utilized to create nine marketed products, including Trokendi XR and Oxtellar XR, as well as other product candidates SPN-810 and SPN-812. The Company markets its products in the United States through its specialty sales force. The Company is subject to regulation by FDA, federal and state government authorities. In addition to regulations in the United States, the Company is subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution of the product candidates to the extent company choose to clinically evaluate or sell any products outside of the United States.
» More Articles for SUPN

Headlines

Articles On GuruFocus.com
Robert Bruce new Buys Feb 16 2015 
Third Quarter Was Robert Bruce's Busiest in 2014 Nov 21 2014 
Supernus Pharmaceuticals Reports Insider Buys Mar 26 2013 

More From Other Websites
SUPERNUS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Feb 08 2016
Supernus Up 3.7%, Federal Court Says Actavis Is Infringing On Patents Feb 08 2016
7:31 am Supernus Pharma confirms that judge ruled that Actavis and subs infringed U.S. Patent Nos.... Feb 08 2016
Supernus Prevails in Oxtellar XR® ANDA Litigation Feb 08 2016
Supernus Pharma upgraded by Jefferies Feb 08 2016
Supernus Pharmaceuticals, Inc.: Fading performance but may be making a comeback? Jan 21 2016
Supernus Pharmaceuticals, Inc. Earnings Analysis: Q3, 2015 By the Numbers Dec 16 2015
SUPERNUS PHARMACEUTICALS INC Financials Dec 08 2015
SUPERNUS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Dec 07 2015
Supernus Announces Distribution of Common Stock by NEA Dec 04 2015
Supernus Announces Distribution of Common Stock by NEA Dec 04 2015
Supernus to Attend Guggenheim Securities Boston Healthcare Conference Dec 02 2015
Supernus to Attend Guggenheim Securities Boston Healthcare Conference Dec 02 2015
Supernus Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : December 1,... Dec 01 2015
Should You Buy Supernus Pharmaceuticals Inc (SUPN)? Nov 21 2015
SUPERNUS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Nov 18 2015
SUPERNUS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Nov 12 2015
Supernus Announces Distribution of Common Stock by NEA Nov 12 2015
Supernus Announces Distribution of Common Stock by NEA Nov 12 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK